|
3-2-10, Dosho-machi, Chuo-ku Osaka 541-8505, Japan Tel. +81-6-6205-5085 Fax +81-6-6205-5262 |
Type: Subsidiary
On the web:
http://www.mt-pharma.co.jp
Employees:
10,361
Japanese drug firm Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku in 2007 and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.
Key numbers for fiscal year ending March, 2008:
Sales: $2,147.5M
Officers:
Representative Director and Chairman: Ryuuichi Tomizawa
President, CEO, and Representative Director: Biopharmaceuticals & Biotherapeutics
Competitors:
Astellas
Chugai
Daiichi Sankyo


